Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...

CORK (29 September 2021) – Boston Scientific Corporation (NYSE: BSX) today announced a €30 million investment in its Cork facility to accelerate the development and manufacturing of...

MARLBOROUGH, Mass. (September 20, 2021) – Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...

MARLBOROUGH, Mass., September 2, 2021 – Boston Scientific (NYSE: BSX) today announced the European launch of FAST Therapy for its WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems. The new...

MARLBOROUGH, Mass., DATE, 2021– Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops...

Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System Study is first to compare interventional therapy in combination with anticoagulation to...

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...

Boston Scientific Initiates European Launch of Spaceoar Vue™ Hydrogel The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing...

Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25 2021 -- Boston Scientific...

Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System MARLBOROUGH, Mass., May 18, 2021 –

LONDON, UK (26 February 2021) The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of TheraSphere™ Y-90 Glass Microspheres for the treatment of...

MARLBOROUGH, Mass., September 30, 2020 – Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The...

Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...

Paris, France., (22 January, 2020) Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark and initiated a limited market release of the EXALT™ Model D Single-Use...

Boston Scientific Corporation announced the CE Mark approval of the Vercise™ Neural Navigator 3 directional Deep Brain Stimulation (DBS) programming software - the first system that integrates...

Arnhem (The Netherlands), 23 September 2019 - Awareness of prostate health is alarmingly low in men over 50, a new survey1 commissioned by the European Association of Urology (EAU) has revealed,...

Boston today announced the launch of the Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System in Europe. The Spectra WaveWriter SCS System is the first and only system for the treatment of...

Boston Scientific today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically...

Boston Scientific Corporation today announced the launch of the GUIDE™ XT System for visualization of Deep Brain Stimulation (DBS) in Europe. The GUIDE XT System is the first DBS visualization...

Arnhem (The Netherlands), 24 September 2018 - Public awareness of urological conditions is alarmingly low throughout Europe. Results of a new international survey of more than 2,500 respondents in...

Boston Scientific today announced positive results from the Bronchial Thermoplasty Global Registry (BTGR) observing patients with severe asthma undergoing treatment with bronchial thermoplasty...

A new study evaluating the safety and performance of the Boston Scientific ACURATE neo2™ Aortic Valve System, a next generation transcatheter aortic valve implantation (TAVI) system,...

Boston Scientific Europe today announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart...

Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device...